Literature DB >> 27993813

High incidence of interstitial lung disease following practical use of osimertinib in patients who had undergone immediate prior nivolumab therapy.

M Kotake1, H Murakami2, H Kenmotsu3, T Naito4, T Takahashi5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 27993813     DOI： 10.1093/annonc/mdw647

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  17 in total

Review 1.  Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ALK-TKIs and ICIs in Non-Small Cell Lung Cancer.

Authors:  Dehua Liao; Lun Yu; Dangang Shangguan; Yongchang Zhang; Bowen Xiao; Ni Liu; Nong Yang
Journal:  Front Pharmacol       Date:  2022-06-06       Impact factor: 5.988

Review 2.  Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care.

Authors:  Mizuki Nishino; Hiroto Hatabu; Lynette M Sholl; Nikhil H Ramaiya
Journal:  Radiographics       Date:  2017 Sep-Oct       Impact factor: 5.333

Review 3.  Imaging of Precision Therapy for Lung Cancer: Current State of the Art.

Authors:  Hyesun Park; Lynette M Sholl; Hiroto Hatabu; Mark M Awad; Mizuki Nishino
Journal:  Radiology       Date:  2019-08-06       Impact factor: 11.105

4.  Osimertinib reactivated immune-related colitis after treatment with anti-PD1 antibody for non-small cell lung cancer.

Authors:  Tomoyoshi Takenaka; Koji Yamazaki; Naoko Miura; Naohiko Harada; Sadanori Takeo
Journal:  Invest New Drugs       Date:  2017-06-10       Impact factor: 3.850

5.  Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab.

Authors:  Nobuaki Mamesaya; Hirotsugu Kenmotsu; Toshiaki Takahashi
Journal:  Invest New Drugs       Date:  2017-05-02       Impact factor: 3.850

6.  Delayed pseudoprogression of lung adenocarcinoma accompanied with interstitial lung disease during chemotherapy after nivolumab treatment.

Authors:  Toru Kumagai; Madoka Kimura; Takako Inoue; Motohiro Tamiya; Kazumi Nishino; Fumio Imamura
Journal:  Thorac Cancer       Date:  2017-03-30       Impact factor: 3.500

7.  Curative effectiveness and safety of osimertinib in the treatment for non-small-cell lung cancer: a meta-analysis of the experimental evidence.

Authors:  Peng Chen; Fuchao Chen; Jiexin Lei; Benhong Zhou
Journal:  Onco Targets Ther       Date:  2018-12-12       Impact factor: 4.147

8.  Different incidence of interstitial lung disease according to different kinds of EGFR-tyrosine kinase inhibitors administered immediately before and/or after anti-PD-1 antibodies in lung cancer.

Authors:  Takahiro Uchida; Kyoichi Kaira; Ou Yamaguchi; Atsuto Mouri; Ayako Shiono; Yu Miura; Kosuke Hashimoto; Fuyumi Nishihara; Yoshitake Murayama; Kunihiko Kobayashi; Hiroshi Kagamu
Journal:  Thorac Cancer       Date:  2019-03-12       Impact factor: 3.500

9.  Case Report: Re-Sensitization to Gefitinib in Lung Adenocarcinoma Harboring EGFR Mutation and High PD-L1 Expression After Immunotherapy Resistance, Which Finally Transform Into Small Cell Carcinoma.

Authors:  Xiaoqian Zhai; Jiewei Liu; Zuoyu Liang; Zhixi Li; Yanyang Liu; Lin Huang; Weiya Wang; Feng Luo
Journal:  Front Oncol       Date:  2021-06-24       Impact factor: 6.244

10.  Identification of Clonal Neoantigens Derived From Driver Mutations in an EGFR-Mutated Lung Cancer Patient Benefitting From Anti-PD-1.

Authors:  Di Wu; Yangyang Liu; Xiaoting Li; Yiying Liu; Qifan Yang; Yuting Liu; Jingjing Wu; Chen Tian; Yulan Zeng; Zhikun Zhao; Yajie Xiao; Feifei Gu; Kai Zhang; Yue Hu; Li Liu
Journal:  Front Immunol       Date:  2020-07-23       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.